(Total Views: 648)
Posted On: 07/28/2025 10:43:02 PM
Post# of 155726
Deals for Phase 1 have brought $1b+. With side-effects.
Cytodyn better not give up any type of control for "$100m", over time. Not a BOD seat. 1st right of refusal. Nothing.
CFO Hoffman is old school.
For 10 years, 10 years, he advised the policy makers on US Govt finance policy rules.
He filed for Cytodyn to leverage it's stand-alone trialing & follow-on deals to be multiples of value.
$100m is nothing in a field of 2m CRC cases yearly. Especially once you confirm cold-hot. Pocket change for a couple trials & to not box your image into being low-balled
Cytodyn better not give up any type of control for "$100m", over time. Not a BOD seat. 1st right of refusal. Nothing.
CFO Hoffman is old school.
For 10 years, 10 years, he advised the policy makers on US Govt finance policy rules.
He filed for Cytodyn to leverage it's stand-alone trialing & follow-on deals to be multiples of value.
$100m is nothing in a field of 2m CRC cases yearly. Especially once you confirm cold-hot. Pocket change for a couple trials & to not box your image into being low-balled
(10)
(0)
